Recommended Vitamin A Dosing for Children Every 6 Months
For children aged 6-11 months, administer 100,000 IU of vitamin A every 6 months; for children aged 12 months to 5 years, administer 200,000 IU every 6 months. This dosing schedule is supported by high-certainty evidence demonstrating a 12% reduction in all-cause mortality 1.
Evidence-Based Dosing Recommendations
The standard WHO-recommended doses are:
- 6-11 months: 100,000 IU (equivalent to 30 mg retinyl acetate) every 6 months
- 12-59 months: 200,000 IU (equivalent to 60 mg retinyl acetate) every 6 months
These doses were validated in the largest trial ever conducted (DEVTA trial), which included 1 million children in India and confirmed the safety and feasibility of this regimen with 86% compliance 2.
Mortality and Morbidity Benefits
The evidence strongly supports this intervention:
- All-cause mortality reduction: 12% (RR 0.88,95% CI 0.83-0.93) based on 19 trials involving over 1.2 million children 1
- Diarrhea mortality reduction: 12% (RR 0.88,95% CI 0.79-0.98) 1
- Measles incidence reduction: 50% (RR 0.50,95% CI 0.37-0.67) 1
- Diarrhea incidence reduction: 15% (RR 0.85,95% CI 0.82-0.87) 1
Important Safety Considerations
Acute Side Effects
The 200,000 IU dose (60 mg) causes transient side effects more frequently than lower doses:
- Vomiting within 48 hours: approximately doubled risk (RR 1.97,95% CI 1.44-2.69) 1
- Nausea and headache occur twice as commonly with 60 mg versus 30 mg 3
- Critical point: These symptoms are self-limited, lasting only 12-24 hours and do not outweigh mortality benefits 3
Gender Considerations
One trial found concerning differential effects by sex, with boys showing potential harm (MRR 1.92) and girls showing benefit (MRR 0.45) 4. However, this finding was not replicated in other large trials 2, 5, and the overall evidence base supports universal supplementation for both sexes.
Practical Implementation
Timing: Administer at routine vaccination contacts or during national immunization campaigns every 6 months 6
Administration: Cut the capsule and drip the oil directly into the child's mouth 2
Contraindications:
- Active nausea/vomiting at time of dosing
- Fever or acute illness on the day of administration 3
Clinical Context
This intervention is one of the most cost-effective in international public health 6. The DEVTA trial demonstrated that even in populations where the mortality reduction was more modest than initially expected (4% vs. 20-30%), the intervention remained beneficial 2. A meta-analysis including DEVTA and eight previous trials confirmed an 11% weighted average mortality reduction (95% CI 5-16%) 2.
Do not withhold supplementation based on concerns about the higher dose in older children—the 200,000 IU dose for children 12-59 months is well-established and the transient side effects are vastly outweighed by mortality benefits 1.